OmniAb Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über OmniAb Inc Unternehmen

OmniAb, Inc. offers a discovery platform that provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable the discovery of next-generation therapeutics. The OmniAb platform is the biological intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate the development of human therapeutic candidates. The Company’s OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach, and OmniTaur features structural attributes of cow antibodies for complex targets. The Company's OmniChicken and OmniClic offer affinity-matured antibodies in an evolutionarily distant chicken host environment, which can deliver a diverse repertoire of antibody panels to conserved therapeutic target antigens.

OmniAb Inc Informationen



BörsenkürzelOABI

Name des UnternehmensOmniAb Inc

IPO-datumOct 09, 2020

CEOMr. Matthew William (Matt) Foehr

Anzahl der mitarbeiter114

WertpapierartOrdinary Share

GeschäftsjahresendeOct 09

Addresse5980 Horton Street

StadtEMERYVILLE

BörseNASDAQ Global Market Consolidated

LandUnited States of America

Postleitzahl94608

Telefon15102507800

Websitehttps://www.omniab.com/

BörsenkürzelOABI

IPO-datumOct 09, 2020

CEOMr. Matthew William (Matt) Foehr

Führungskräfte von OmniAb Inc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. John L. Higgins

Chairman of the Board

2.85M

+0.71%

Mr. Kurt A. Gustafson

Executive Vice President - Finance, Chief Financial Officer

223.83K

-12.04%

Dr. Carolyn R. Bertozzi, Ph.D.

Independent Director

93.31K

+23.52%

Mr. Steven (Steve) Love

Independent Director

71.67K

+22.86%

Dr. Philip J. (Phil) Gotwals, Ph.D.

Independent Director

--

Mr. Matthew William (Matt) Foehr

President, Chief Executive Officer, Director

--

Mr. Charles Stuart Berkman, J.D.

Chief Legal Officer, Secretary

--

Dr. Jennifer Cochran, Ph.D.

Independent Director

--

Mr. Steven C. Crouse

Independent Director

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. John L. Higgins

Chairman of the Board

2.85M

+0.71%

Mr. Kurt A. Gustafson

Executive Vice President - Finance, Chief Financial Officer

223.83K

-12.04%

Dr. Carolyn R. Bertozzi, Ph.D.

Independent Director

93.31K

+23.52%

Mr. Steven (Steve) Love

Independent Director

71.67K

+22.86%

Dr. Philip J. (Phil) Gotwals, Ph.D.

Independent Director

--

Mr. Matthew William (Matt) Foehr

President, Chief Executive Officer, Director

--

Umsatzaufteilung

Währung: USDAktualisiert: Mon, Oct 6

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Service revenue

1.94M

49.68%

License and milestone revenue

1.24M

31.87%

xPloration revenue

608.00K

15.60%

Royalty revenue

111.00K

2.85%

Keine Daten

Nach Geschäftsbereich

Nach Region

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

Service revenue

1.94M

49.68%

License and milestone revenue

1.24M

31.87%

xPloration revenue

608.00K

15.60%

Royalty revenue

111.00K

2.85%

Aktionärsstatistik

Aktualisiert: Mon, Sep 8

Aktionäre

Aktionärstypen

Aktionäre

Anteil

Avista Capital Holdings, LP

10.99%

Whitefort Capital Management, LP

7.11%

Ash X LP

5.75%

BlackRock Institutional Trust Company, N.A.

4.40%

The Vanguard Group, Inc.

3.66%

Andere

68.09%

Aktionäre

Anteil

Avista Capital Holdings, LP

10.99%

Whitefort Capital Management, LP

7.11%

Ash X LP

5.75%

BlackRock Institutional Trust Company, N.A.

4.40%

The Vanguard Group, Inc.

3.66%

Andere

68.09%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor

16.23%

Hedge Fund

14.30%

Private Equity

12.89%

Investment Advisor/Hedge Fund

12.76%

Corporation

8.21%

Individual Investor

6.69%

Research Firm

1.01%

Pension Fund

0.14%

Venture Capital

0.11%

Andere

27.66%

Institutionelle Beteiligung



Aktualisiert: Wed, Oct 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q3

349

70.66M

57.59%

-18.22M

2025Q2

348

92.68M

75.53%

-5.84M

2025Q1

359

87.33M

71.43%

-8.58M

2024Q4

365

89.85M

74.79%

-8.38M

2024Q3

394

90.25M

75.21%

-25.05M

2024Q2

389

89.07M

76.08%

-29.09M

2024Q1

378

93.24M

79.93%

-23.55M

2023Q4

374

92.06M

79.14%

-28.03M

2023Q3

352

92.71M

80.23%

-26.22M

2023Q2

337

91.30M

79.07%

-24.17M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

Avista Capital Holdings, LP

15.82M

12.89%

--

Sep 30, 2024

Whitefort Capital Management, LP

10.24M

8.35%

+6.33M

+161.57%

Jun 30, 2025

Ash X LP

8.27M

6.74%

+2.86M

+52.77%

Aug 26, 2025

BlackRock Institutional Trust Company, N.A.

6.33M

5.16%

-122.32K

-1.89%

Jun 30, 2025

The Vanguard Group, Inc.

5.27M

4.29%

+89.01K

+1.72%

Jun 30, 2025

Foehr (Matthew W)

4.34M

3.53%

+540.54K

+14.24%

Aug 26, 2025

Dimensional Fund Advisors, L.P.

2.91M

2.37%

-217.95K

-6.96%

Jun 30, 2025

Higgins (John L)

2.85M

2.32%

+20.00K

+0.71%

Jun 17, 2025

Private Management Group, Inc.

2.56M

2.08%

+28.29K

+1.12%

Jun 30, 2025

Geode Capital Management, L.L.C.

2.44M

1.99%

-21.63K

-0.88%

Jun 30, 2025

Verbundene ETFs



Aktualisiert: Thu, Nov 6

Name

Anteil

iShares Micro-Cap ETF

0.03%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

0.02%

ProShares Ultra Nasdaq Biotechnology

0.02%

Invesco Nasdaq Biotechnology ETF

0.02%

Invesco RAFI US 1500 Small-Mid ETF

0.01%

Proshares Ultra Russell 2000

0.01%

ProShares UltraPro Russell2000

0.01%

Fidelity Enhanced Small Cap ETF

0.01%

Global X Russell 2000 ETF

0.01%

iShares Russell 2000 Value ETF

0.01%

iShares Micro-Cap ETF

Anteil0.03%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

Anteil0.02%

ProShares Ultra Nasdaq Biotechnology

Anteil0.02%

Invesco Nasdaq Biotechnology ETF

Anteil0.02%

Invesco RAFI US 1500 Small-Mid ETF

Anteil0.01%

Proshares Ultra Russell 2000

Anteil0.01%

ProShares UltraPro Russell2000

Anteil0.01%

Fidelity Enhanced Small Cap ETF

Anteil0.01%

Global X Russell 2000 ETF

Anteil0.01%

iShares Russell 2000 Value ETF

Anteil0.01%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Art

Verhältnis

Keine Daten

Datum

Art

Verhältnis

Keine Daten